All In Biotech

Drug Trial Radar · NCT06700538

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-INHBE in Adult Volunteers With Obesity With and Without Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

190

Actual

Start

Dec 4, 2024

Primary completion

Oct 15, 2027

Study completion Feb 15, 2028

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (in Part 1), the safety, tolerability, PK, and PD of multiple doses of ARO-INHBE either as monotherapy, or in combination with tirzepatide, in adult participants with obesity with and without type 2 diabetes mellitus (in Part 2 and Part 3).

Conditions

  • Obesity

Interventions

  • ARO-INHBEDrug

    Subcutaneous (SC) injection

  • PlaceboDrug

    Calculated volume to match active treatment by SC injection

  • TirzepatideDrug

    SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Day 365

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Camberwell, Australia

  • Research Site

    Charlestown, Australia

  • Research Site

    Maroochydore, Australia

  • Research Site

    Sydney, Australia

  • Research Site

    Chicoutimi, Canada

  • Research Site

    Concord, Canada

  • Research Site

    Toronto, Canada

  • Research Site

    Tbilisi, Georgia

  • Research Site 2

    Tbilisi, Georgia

  • Research Site

    Tbilisi, Georgia

  • Research Site

    Tbilisi, Georgia

  • Research Site

    Auckland, New Zealand

  • Research Site

    Auckland, New Zealand

  • Research Site

    Christchurch, New Zealand

  • Research Site

    Grafton, Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.